Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: EN Brussels
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

ThromboGenics NV

+ Add to Watchlist

THR:BB

5.3030 EUR 0.1100 2.03%

As of 11:35:00 ET on 05/05/2015.

Snapshot for ThromboGenics NV (THR)

Open: 5.4500 Day's Range: 5.3020 - 5.5060 Volume: 64,919
Previous Close: 5.4130 52wk Range: 4.7500 - 23.9500 1-Yr Rtn: -77.14%

Stock Chart for THR

No chart data available.
  • THR:BB 5.3030
  • 1D
  • 1M
  • 1Y
5.4130
Interactive THR Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for THR

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. BEL20 -
Earnings Per Share (EUR) (ttm) -1.4200
Est. EPS (EUR) (12/2015) -1.1150
Est. PEG Ratio -
Market Cap (M EUR) 191.41
Shares Outstanding (M) 36.09
30 Day Average Volume 154,066
Price/Book (mrq) 0.9202
Price/Sale (ttm) 13.8943
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/28/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for THR

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for THR

ThromboGenics NV is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company is focused on developing medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system.

Patrik De HaesCEO/Executive DirectorDominique VanfleterenChief Financial Officer
Claude SanderChief Legal OfficerLaurence RaemdonckHead:Human Resources
More Company Profile & Key Executives for THR

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil